title: Evolving calciphylaxis--what randomized, controlled trials can contribute to the capture of rare diseases.
authors.affiliation: Division of Nephrology, Klinikum Coburg GmbH, Coburg, Germany markus.ketteler@klinikum-coburg.de.
authors.forename: Markus
authors.initials: M
authors.lastname: Ketteler
authors.affiliation: Division of Nephrology, Klinikum Coburg GmbH, Coburg, Germany.
authors.forename: Patrick H
authors.initials: PH
authors.lastname: Biggar
mesh_terms: D057966:Calcimimetic Agents / Q000627:therapeutic use*; D002115:Calciphylaxis / Q000453:epidemiology*; D000069449:Cinacalcet / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male
chemical_list: D057966:Calcimimetic Agents; D000069449:Cinacalcet
keywords: calcimimetics; hemodialysis; hyperparathyroidism; parathyroid hormone; vascular calcification